MRTX 0902
Alternative Names: BMS-986509; MRTX-0902Latest Information Update: 25 Nov 2025
At a glance
- Originator Mirati Therapeutics
- Developer Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action SOS1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 30 Oct 2025 Discontinued - Phase-I/II for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (unspecified route) (Bristol-Myers Squibb pipeline, November 2025)
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb